Calamos Advisors’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$823K Sell
8,546
-2,242
-21% -$224K ﹤0.01% 817
2025
Q4
$1.05M Sell
10,788
-668
-6% -$57.3K ﹤0.01% 686
2025
Q3
$815K Buy
11,456
+2,589
+29% +$173K ﹤0.01% 727
2025
Q2
$530K Buy
8,867
+4,389
+98% +$241K ﹤0.01% 742
2025
Q1
$235K Sell
4,478
-118
-3% -$6.63K ﹤0.01% 790
2024
Q4
$253K Sell
4,596
-435
-9% -$22.9K ﹤0.01% 786
2024
Q3
$253K Buy
+5,031
New +$232K ﹤0.01% 774
2024
Q2
Sell
-5,073
Closed -$223K 973
2024
Q1
$223K Sell
5,073
-30,129
-86% -$1.33M ﹤0.01% 763
2023
Q4
$1.67M Sell
35,202
-735
-2% -$30.9K 0.01% 619
2023
Q3
$1.59M Buy
35,937
+3,000
+9% +$139K 0.01% 637
2023
Q2
$1.57M Buy
32,937
+1,728
+6% +$77.9K 0.01% 672
2023
Q1
$1.23M Buy
31,209
+18,552
+147% +$674K 0.01% 782
2022
Q4
$358K Sell
12,657
-60,105
-83% -$1.72M ﹤0.01% 921
2022
Q3
$2.19M Sell
72,762
-7,705
-10% -$268K 0.01% 861
2022
Q2
$2.73M Sell
80,467
-7,099
-8% -$254K 0.01% 864
2022
Q1
$3.93M Buy
87,566
+17,822
+26% +$824K 0.01% 785
2021
Q4
$3.22M Buy
+69,744
New +$2.81M 0.01% 802
2019
Q1
Sell
-11,740
Closed -$287K 678
2018
Q4
$287K Hold
11,740
﹤0.01% 625
2018
Q3
$436K Buy
+11,740
New +$317K ﹤0.01% 599

Other funds holding IRMD

Calamos Advisors's IRMD Position: Q1 2026 in Review

Calamos Advisors reduced its iRadimed (IRMD) stake by 21% in Q1 2026, selling an estimated $224K and leaving 8,546 shares worth $823K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Calamos Advisors first reported a position in IRMD in Q3 2018 and has held it in 19 quarters since. The position peaked at $3.93M in Q1 2022. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Calamos Advisors held 8,546 shares of iRadimed worth $823K as of Q1 2026.
  • Calamos Advisors sold 2,242 iRadimed shares in Q1 2026, an estimated $224K.
  • iRadimed made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #817 holding.
  • Calamos Advisors first reported a position in iRadimed in Q3 2018 and has held it in 19 quarters since.
  • Calamos Advisors's iRadimed position peaked at $3.93M in Q1 2022.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.